Citations

Clear

2156 citation(s) found for "Sułek, Anna".

Severe and very severe ME/CFS – when healthcare is out of reach: A qualitative study
Hackl, Verena , Hainzl, Astrid, Wojczewski, Silvia , Maukner, Anna, Mair, Lucia, Saugstad, Ola Didrik , Grach, Stephanie L. , Hoffmann, Kathryn

Mayo Clinic

No container title available | November 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-11494085/v1 Get It

Abstract Severe and very severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) causes profound functional impairment and substantial multisystem manifestations, leaving many home- or bed-bound, highly dependent on family/lay caregivers, and often invisible to healthcare. This qualitative study explored healthcare experiences, unmet needs, and barriers to healthcare access among people with severe and very severe ME/CFS, their family/lay caregivers, and healthcare professionals in Austria. Adapted narrative and semi-structured interviews were conducted alongside focus groups and expert interviews with healthcare professionals. Data were analysed using qualitative thematic analysis. Our findings suggest that knowledge gaps, absent or limited transportability, and insufficiently adapted healthcare services restricted access to necessary care, and could even make healthcare itself a risk for deterioration. Family/Lay caregivers frequently assumed coordinative, nursing, and medical responsibilities in the absence of accessible professional support. Improving provision for this population requires models designed around the functional capacities and individual needs of people with severe and very severe ME/CFS, including home-based and outreach care, telemedicine, multidisciplinary coordination, adapted routine and emergency care, and ME/CFS-specific professional education. Future studies should evaluate such models and strengthen research inclusion, particularly of people with very severe ME/CFS.
Comparing Patient and Provider Opinions and Experiences with Post-Cochlear Implant Auditory Training
Dornhoffer, James R. , Archang, Maani, Davide, Anna , Richlin, Blair C. , Moberly, Aaron C.

Mayo Clinic

Otology & Neurotology Open | November 5, 2026 | Volume: 6 | Issue: 4 | Pages: e101

10.1097/ono.0000000000000101 Get It

Objective: To compare patient and provider experiences and opinions regarding auditory training in adult cochlear implant (CI) recipients. Study Design: Narrative review and comparison of patient and provider surveys. Setting: Tertiary referral center and email distribution list of the American Cochlear Implant Alliance. Participants: CI recipients and care providers. Interventions/Methods: We examined and performed a narrative review of two independently developed and published surveys looking at auditory training practices and habits from the perspectives of CI recipients and CI providers, respectively. Main Outcome Measure: Comparison of overlapping topics between patient and provider reports on their experiences with respect to auditory training for CI recipients. Results: Topics for comparison included how auditory training was performed, the timing or logistics of training, and barriers to utilization of training. Findings revealed that auditory training is considered a valuable resource by both CI patients and providers, with similar reports from the 2 groups on the use, timing, and perceived benefits of auditory training. However, we also noted discrepancies between patients and providers with regard to the use of specific types of training and concerns regarding reimbursement for auditory training services. Conclusion: Both CI patients and providers consider auditory training a useful and affordable resource to maximize CI outcomes. However, utilization remains inconsistent. Further study and effort are needed to address key knowledge gaps and better standardize this aspect of peri-CI care.
A Comparison of Two Strategies for Converting to Adalimumab Biosimilarsa
Erickson, Sara J, Rovey, Heather D H, Ramel, Cassandra L , Buechel, Bryan J, Swenson, Kelci A, Bartoo, Anna, Davis, John M.

Mayo Clinic

American Journal of Health-System Pharmacy | November 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ajhp/zxag384 | PMID 42994452 Get It

Abstract Purpose We retrospectively compared 2 strategies for adalimumab biosimilar conversion at an academic medical center to better understand the effects of each strategy. Methods The formulary for our institution is managed by physician- and pharmacist-led task forces, in collaboration with our specialty pharmacy and pharmacy benefit manager. We implemented 2 phased strategies to increase adalimumab biosimilar utilization. First, we added preferred biosimilars to the formulary at parity to reference product and relied on prescribers to promote conversion. Second, we added an interchangeable biosimilar and removed reference product from the formulary while leveraging specialty pharmacy workflows for prescription conversions, streamlined facility inventory, and minimized dependence on prescriber workflows. For both strategies, we evaluated prescribing trends, dispensing data, and pharmaceutical spend for all medical center patients, specialty pharmacy patients, and patients with the top 3 specialty pharmacy payers. Results During phase 1 (quarter [Q] 2 of 2023 [2Q23] to 1Q24), reference product dispensing remained largely unchanged (<5% reduction). Phase 2 (2Q24 to 2Q25) resulted in a significant reduction in specialty pharmacy dispenses of reference product, from 95.7% to 19.0%. This phase also resulted in a 76.0% reduction in medical center adalimumab/biosimilar spend. At the end of phase 2, biosimilar accounted for 42.6% of all medical center patient prescriptions. Total dispensed units of reference product/biosimilar were modestly decreased (6%) during phase 2. Conclusion Formulary and clinical support for adalimumab biosimilar alone did not promote use over the reference product, but rapid and substantial biosimilar uptake was achieved after operational barriers were addressed.
In the Singular
Ligocki, Anna Maria

Mayo Clinic

Anesthesiology | September 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/aln.0000000000006312 | PMID 42808768 Get It

Ventricular Fibrillation Mapping in a Large-Animal Model Using Dual Mechanical Circulatory Support: Electroanatomic Substrate Preservation Without Ischemic Changes
Quelal, Karol , Tri, Jason , Haq, Ikram-Ul , Welle, Amalia, Niu, Hanxu, Behfar, Atta , Yalamuri, Suraj , Ward, Robert C. , Ezzeddine, Fatima M. , Tolkacheva, Elena G. , Tan, Nicholas Y. , Munoz, Freddy Del‐Carpio , Asirvatham, Samuel J. , DeSimone, Christopher V. , Quelal, Karol , Tri, Jason A , Haq, Ikram U , Ward, Robert C , Ezzeddine, Fatima , Tolkacheva, E G , Del-Carpio Munoz, Freddy , Asirvatham, Samuel J , Behfar, Atta , Welle, Amalia A., Yalamuri, Suraj

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | September 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/circep.126.014954 | PMID 42755696 Get It

BACKGROUND: Ventricular fibrillation (VF) remains a leading cause of sudden cardiac death with an incompletely characterized electrophysiological substrate. Traditional large-animal VF models are limited by hemodynamic collapse and myocardial ischemia. This study establishes a reproducible swine model using dual mechanical circulatory devices to enable high-density electroanatomic mapping under nonischemic conditions. METHODS: Five Yorkshire swine (55–65 kg) underwent sustained VF supported by venoarterial extracorporeal membrane oxygenation (2.5–3.0 L/min) and percutaneous left ventricular unloading (Impella CP, P-2–P-4). High-density electroanatomic mapping using CARTO 7 was performed at baseline and after defibrillation. Bipolar voltage was acquired from 7 predefined ventricular regions (21 measurements per animal per time point; n=210 paired observations). Unipolar voltage mapping and continuous surface ECG monitoring were used to assess acute ischemic injury. Systemic perfusion was maintained at systolic arterial pressure ≥80 mm Hg. Linear mixed-effects modeling was used to analyze voltage changes from pre-VF to post-VF. RESULTS: Sustained VF (10±1 minutes) was reproducibly induced and maintained with consistent hemodynamics (systolic arterial pressure, 90±5 mm Hg; extracorporeal membrane oxygenation flow, 2.5±0.5 L/min). All animals were successfully defibrillated. High-density mapping was feasible in all experiments (1000±300 points per chamber). Bipolar voltage showed no change from pre-VF (5.86±2.56 mV) to post-VF (6.53±2.22 mV; mean difference, 0.67 mV [95% CI, –0.31 to 1.65]; P =0.15). Both left ( P =0.17) and right ventricles ( P =0.08) demonstrated voltage preservation. Regional analysis showed no significant changes (all P >0.05); post-VF voltages remained above viability thresholds (>1.5 mV). Unipolar voltage maps recovered toward baseline, with no ECG injury pattern identified after defibrillation. CONCLUSIONS: Dual mechanical circulatory support with venoarterial extracorporeal membrane oxygenation and Impella CP enables reproducible, high-fidelity electroanatomic mapping and preserves myocardial substrate after sustained VF in a large-animal model. This platform overcomes key technical barriers in VF research, providing a nonischemic foundation for future mechanistic and translational studies.
Targeting SYK enhances responses to radiotherapy and PD-1 blockade with myeloid immune remodeling in breast cancer
Zhou, Qin, Dibbs, Anna, Yin, Ping, Pavelko, Kevin D. , Dong, Haidong , Luo, Kuntian, Tu, Xinyi , Lucien, Fabrice , Park, Sean S. , Grams, Michael P. , Xu‐Welliver, Meng , Callaghan, Cameron , Lou, Zhenkun, Mutter, Robert W., Han, Yiqun , Zhu, Shouhai , Yin, Ping, Lou, Zhenkun , Mutter, Robert W. , Lucien-Matteoni, Fabrice

Mayo Clinic

Frontiers in Immunology | September 18, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fimmu.2026.1929236 | PMID 42827904 Get It

Introduction Spleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase involved in immune signaling and has been implicated in tumor-intrinsic resistance to DNA-damaging therapies. Although SYK activity has been associated with poor outcomes in triple-negative breast cancer (TNBC), its role in resistance to combined radiotherapy and immune checkpoint blockade remains unclear. Methods SYK expression and clinical relevance were assessed across multiple breast cancer cohorts, including radiotherapy-treated datasets. Integrated transcriptomic analyses were used to characterize SYK-associated immune states. The functional effects of pharmacologic SYK inhibition were evaluated using in vitro assays and an immunocompetent bilateral 4T1 tumor model in female BALB/c mice treated with radiotherapy and PD-1 blockade. Treatment-associated immune remodeling was assessed by flow cytometry and transcriptomic profiling. Results Across multiple cohorts, elevated SYK expression, particularly in TNBC, was associated with inferior clinical outcomes and immune dysregulation. Pharmacologic SYK inhibition enhanced tumor responses to radiotherapy and PD-1 blockade at both irradiated and distant tumor sites. These effects were accompanied by coordinated remodeling of the tumor immune microenvironment, including suppression of neutrophil-associated signatures and reductions in immunosuppressive myeloid populations, including M2-like macrophages and myeloid-derived suppressor cells. Discussion Pharmacologic SYK inhibition enhances responses to radiotherapy and PD-1 blockade in preclinical TNBC models and is accompanied by remodeling of the immunosuppressive myeloid compartment. These findings support further investigation of SYK-targeted strategies to improve responses to combined radiotherapy and immune checkpoint blockade.
Pearls & Oy-sters: DPPX Antibody-Associated Encephalitis in a Patient With Diarrhea, Tremor, Ocular Flutter, and Cognitive-Psychiatric Changes
Sosa, Santiago Martinez , Webb, Lauren M. , Thomsen, Anna, Rigler, Nicole, Coon, Elizabeth A. , Toledano, Michel , McKeon, Andrew , Banks, Samantha A. , Martinez Sosa, Santiago , Paz Soldán, M Mateo , Coon, Elizabeth Anne , Toledano, Michel , McKeon, Andrew , Syc-Mazurek, Stephanie B , Banks, Samantha , Soldán, M. Mateo Paz , Syc‐Mazurek, Stephanie B.

Mayo Clinic

Neurology | September 1, 2026 | Volume: 107 | Issue: 7 | Pages: No page available

10.1212/wnl.0000000000218522 | PMID 42679339 Get It

MicroRNA Control of Hepatocyte–Stromal Crosstalk in the Early Premalignant Microenvironment of HBV-Associated HCC
Sartorius, Kurt , Kramvis, Anna , Chuturgoon, Anil A. , Chuturgoon, Anil

Mayo Clinic

International Journal of Molecular Sciences | August 24, 2026 | Volume: 27 | Issue: 17 | Pages: 7581

10.3390/ijms27177581 | PMID 42737483 Get It

Chronic hepatitis B virus (CHB) infection remains a major cause of hepatocellular carcinoma (HCC), yet the premalignant microenvironment that links to HBV-associated HCC (HBV-HCC) is still poorly defined. This review synthesizes evidence that HBV-infected hepatocytes function as signaling hubs that, through microRNA (miRNA)-regulated crosstalk with Kupffer cells, liver sinusoidal endothelial cells, hepatic stellate cells and cancer-associated fibroblasts (CAFs), progressively remodel the liver from an antiviral tissue into a premalignant and early tumor microenvironment. Across the HBV-HCC continuum, a core set of dysregulated miRNAs, including miR-21, miR-29a/b, miR-122, miR-146a, miR-155, miR-200a, miR-126, miR-210 and the miR-130/301 family, coordinates transition from innate antiviral responses to HSC activation, extracellular matrix deposition, mechanotransduction, angiogenesis, chronic inflammation and cancer-associated CAF programing. By mapping these stage-specific miRNA networks onto acute infection, CHB, early fibrogenesis, advanced fibrosis and CAF-rich dysplastic states, the review reframes HBV-HCC pathogenesis as a sequence of miRNA-guided hepatocyte–stromal states rather than a purely hepatocyte-intrinsic process. This perspective suggests that composite, cell-type-resolved miRNA signatures in serum or liver tissue could serve as biomarkers for identifying CHB patients who are entering a premalignant microenvironment before conventional surveillance markers become abnormal. It further highlights miRNA hubs that couple antiviral, fibrogenic, angiogenic and CAF-associated signaling as potential therapeutic targets for reprograming the HBV-driven premalignant microenvironment, with the long-term goal of intercepting HBV-HCC development at earlier, microenvironmentally defined stages.
Epidemiologic Study of Transfusion-Related Alpha-Gal Syndrome
Kaufman, Richard M., Hoen, Anne G., Khan, Jenna, Knudson, C. Michael, Romero, Andres E. Mindiola, Mo, Allison , Takanashi, Minoko , Collaborative, UPTICK Study Group; for the Biomedical Excellence for Safer Transfusion (BEST), Cardigan, Rebecca, Stanworth, Simon J., Commins, Scott P. , Scherer, Emily A., Davenport, Robertson D., Afraz, Sajjad, Andrews, Jennifer , Casey, John, Sullivan, Jensyn Cone , Cousins, Clara C. , Giorgi, Valeria De , Delaney, Meghan, DelBaugh, Regina M. , Gilstad, Colleen W. , Gofton, Alexander , Hill, Kate, Hogan, Keenan , Humbrecht, Catherine , Ikeda, Kazuhiko, Javanbakht, Ayda, Juskewitch, Justin E, Wojtowicz, Monique M. Menzies, Miller, Maureen J., Mills, Georgia, Nelson, Anna C. , Pauly, Marie C., Poisson, Jessica , Raval, Jay S., Samy, Nikitha, Sato, Tomohiko, Takeda, Yoshinori , Thibodeaux, Suzanne R. , Nunen, Sheryl van, Virk, Mrigender S., West-Mitchell, Kamille, Yamanouchi, Jun, Yoshihara, Satoshi, Zheng, X. Long, Ziman, Alyssa, Cone Sullivan, Jensyn , Kaufman, Richard Max , Hoen, Anne Gatewood , Knudson, Charles Michael , Metcalf, Ryan A. , Schäfer, Richard , Dunbar, Nancy M. , Cardigan, Rebecca A. , Stanworth, Simon J., Scherer, Emily A. , Cervinski, Mark A , Arai, Yasuyuki , Brugnara, Carlo , Allen, Elizabeth S. , Aurich, Konstanze , Casey, John , Cohn, Claudia S. , Crowe, Elizabeth P , Delaney, Meghan , Hendrickson, Jeanne E. , Hill, Kate, Ikeda, Kazuhiko , Jacquot, Cyril , Javanbakht, Ayda , Juskewitch, Justin E. , Lu, Wen , Wojtowicz, Monique Menzies , Miller, Maureen J. , Nelson, Anna , Pagano, Monica B. , Pauly, Marie-Christin , Saifee, Nabiha H , Sato, Tomohiko, Takeda, Yoshinori, Tiberghien, Pierre , Nunen, Sheryl van, Virk, Mrigender , Wood, Erica M , Yoshihara, Satoshi , Zheng, X. Long, Ziman, Alyssa

Mayo Clinic

JAMA Internal Medicine | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamainternmed.2026.3983 | PMID 42636004 Get It

Importance Recent case reports suggest that B antigen–containing blood products may be associated with anaphylactic transfusion reactions in recipients with preformed immunoglobulin E to galactose- α -1,3-galactose (alpha-gal). Objective To test the association of local alpha-gal syndrome (AGS) prevalence and allergic transfusion reaction (ATR) in patients with blood type O. Design, Setting, and Participants In this international, multicenter, retrospective cohort study at academic medical centers, sites were assigned to AGS high- or low-prevalence clusters based on the known geographic distribution of AGS. Data were collected on platelet or plasma transfusions and ATRs during 2020 to 2024. Consecutive patients receiving platelet or plasma transfusions were included. Exposures Patients with blood type O who received B or AB units and patients with blood type O who received O units (reference group) in AGS high- and low-prevalence clusters were compared. Main Outcomes and Measures Before data collection, the hypothesis was that if transfusion-related alpha-gal syndrome (TRAGS) is a true clinical entity, excess ATRs to group B or AB units would be detected in AGS high-prevalence regions exclusively. The main measure was the overall risk ratio (RR) for ATRs to B or AB plasma or platelets in AGS high- vs low-prevalence clusters. Results In total, 558 823 platelet and plasma transfusions at 40 sites in 5 countries were analyzed, of which ATRs occurred in 1744 transfusions (0.3%). In the US AGS high-prevalence cluster (9 sites), significantly more ATRs of any severity occurred among patients with blood type O who received B or AB units vs patients with blood type O who received O units (overall RR, 3.93; 95% CI, 2.96-5.21; P < .001). In contrast, in the primary analysis of the AGS low-prevalence cluster (15 sites), excess ATRs to B or AB units were not detected. In subgroup analyses among patients with blood type O receiving B units, the RR for moderate to severe ATRs was 9.14 (95% CI, 5.39-15.52; P < .001) in the AGS high-prevalence cluster vs 2.15 (95% CI, 1.34-3.47; P = .002) in the AGS low-prevalence cluster. Outside the US, a signal consistent with TRAGS was not detected. Conclusions and Relevance This cohort study provides provocative epidemiologic evidence that TRAGS may be a unique manifestation of AGS and a previously unrecognized risk associated with transfusion. In AGS high-prevalence regions, blood collectors and hospital transfusion services should consider approaches to preventing severe ATRs from B or AB plasma or platelet units.